CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

New York Jets

The New York Jets are a professional football team headquartered in Florham Park, New Jersey, representing the New York metropolitan area. It is a privately owned business with under 200 employees. Founded more than 50 years ago, the Jets franchise has defined itself as a trailblazer, trendsetter and leader in the regions sports landscape and across the NFL. Since Chairman and CEO Woody Johnson purchased the team in 2000, the team has undergone a major revitalization and rebranding, focused on winning both on and off the field. For Johnson, capturing the franchises second championship is priority #1. Under his ownership, the team has posted seven winning seasons, appeared in seven postseason games, including two AFC Championship Game appearances, and winning an AFC East division title in 2002. They have also made strides off the field with the opening of two state-of-the-art homes: the Atlantic Health Jets Training Center in 2008 and MetLife Stadium in 2010. Honored as one of NJ Bizs 2018 Best Places to Work in New Jersey. This award recognizes and honors New Jersey-based employers who show dedication to their employees professional growth and quality of life.

Purpose Legal

Purpose Legal is a prominent provider of legal support services, focusing on eDiscovery, document review, and legal technology solutions. Founded by attorneys over a decade ago and based in Austin, TX, the company aims to enhance the efficiency of legal services through a skilled and diverse team. Purpose Legal is recognized for its commitment to diversity, with 89% of its workforce representing various backgrounds and 63% being female. The company offers a comprehensive range of services tailored to corporate legal departments and law firms. These services include secure eDiscovery solutions, thorough document reviews, and customized legal technology solutions. Purpose Legal also provides litigation support, information governance, data breach discovery, and commercial contract review. Additionally, the company applies data science techniques to improve legal operations and decision-making. Purpose Legal is trusted by a wide array of clients, including multinational corporations and government entities, and has received several prestigious certifications, ensuring high standards of quality and security.

27North Inc.

27North Inc. is a luxury expedition vehicle manufacturer, providing durable and luxurious vehicles tailored to suit adventure seekers, leisurely travelers, and mobile lifestyle enthusiasts. Since 2017, our team has provided our clients with the highest quality, first-class service. With our comprehensive offerings, you can expect to receive superior customer service from the initial contact and beyond.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.